We are live on ! Find out more
VIA

Virtus Investment Advisers Portfolio holdings

AUM $363M
1-Year Est. Return 34.89%
This Fund
S&P 500
This Quarter Est. Return
+6.98%
1 Year Est. Return
+34.89%
3 Year Est. Return
+131.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$368M
AUM Growth
+$18.7M
Cap. Flow
+$14.9M
Cap. Flow %
4.04%
Top 10 Hldgs %
6.4%
Holding
553
New
113
Increased
199
Reduced
149
Closed
92

Top Buys

Rank Stock Value
1
EXPD icon
Expeditors International
EXPD
+$2.17M
2
INCY icon
Incyte
INCY
+$2.09M
3
WAT icon
Waters Corp
WAT
+$2.03M
4
AMAT icon
Applied Materials
AMAT
+$2.01M
5
LVS icon
Las Vegas Sands
LVS
+$2.01M

Top Sells

Rank Stock Value
1
TSLA icon
Tesla
TSLA
+$2.5M
2
EA
Electronic Arts
EA
+$2.43M
3
FOXA icon
Fox Class A
FOXA
+$2.05M
4
MS icon
Morgan Stanley
MS
+$2.04M
5
ATO icon
Atmos Energy
ATO
+$2.02M

Sector Composition

Rank Sector Weight
1 Healthcare 26.73%
2 Financials 22.73%
3 Technology 18.16%
4 Industrials 8.89%
5 Consumer Discretionary 7.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TYRA icon
251
Tyra Biosciences
TYRA
$1.58B
$309K 0.08%
11,756
+741
+7% +$13.6K
PHVS icon
252
Pharvaris
PHVS
$2.44B
$306K 0.08%
11,011
+4,407
+67% +$106K
EYPT icon
253
EyePoint Inc
EYPT
$1.2B
$304K 0.08%
16,638
+3,795
+30% +$53.8K
PGEN icon
254
Precigen
PGEN
$2.59B
$301K 0.08%
+72,095
New +$279K
BLTE
255
Belite Bio
BLTE
$6.54B
$301K 0.08%
1,882
+51
+3% +$6.04K
CAPR icon
256
Capricor Therapeutics
CAPR
$237M
$295K 0.08%
10,224
+2,061
+25% +$26.9K
RCUS icon
257
Arcus Biosciences
RCUS
$3.64B
$294K 0.08%
12,356
+187
+2% +$3.81K
VTYX
258
DELISTED
Ventyx Biosciences
VTYX
$293K 0.08%
+32,483
New +$243K
IMNM icon
259
Immunome
IMNM
$2.83B
$292K 0.08%
13,593
+1,970
+17% +$34.6K
SEPN
260
Septerna Inc
SEPN
$1.75B
$292K 0.08%
+10,457
New +$250K
PRAX icon
261
Praxis Precision Medicines
PRAX
$10.1B
$291K 0.08%
989
-1,538
-61% -$286K
XERS icon
262
Xeris Biopharma Holdings
XERS
$1.45B
$291K 0.08%
37,102
+11,358
+44% +$89.4K
ANAB icon
263
AnaptysBio
ANAB
$1.68B
$287K 0.08%
5,919
+1,059
+22% +$41.3K
ENGN icon
264
enGene Therapeutics
ENGN
$121M
$284K 0.08%
+31,445
New +$252K
DFTX
265
Definium Therapeutics
DFTX
$6.12B
$284K 0.08%
21,198
+5,611
+36% +$69.4K
MAZE
266
Maze Therapeutics
MAZE
$1.59B
$284K 0.08%
6,846
-1,551
-18% -$53.3K
IVVD icon
267
Invivyd
IVVD
$218M
$283K 0.08%
+114,668
New +$238K
PVLA
268
Palvella Therapeutics
PVLA
$2.27B
$282K 0.08%
+2,698
New +$230K
MBX
269
MBX Biosciences
MBX
$3.27B
$281K 0.08%
8,910
-1,704
-16% -$41.3K
TECX
270
Tectonic Therapeutic
TECX
$606M
$281K 0.08%
13,462
+8,391
+165% +$156K
RLAY icon
271
Relay Therapeutics
RLAY
$4.33B
$280K 0.08%
33,130
+148
+0.4% +$1.06K
EWTX icon
272
Edgewise Therapeutics
EWTX
$4.73B
$279K 0.08%
11,263
+3,883
+53% +$77.9K
RIGL icon
273
Rigel Pharmaceuticals
RIGL
$750M
$279K 0.08%
+6,524
New +$246K
IMTX icon
274
Immatics
IMTX
$1.32B
$278K 0.08%
26,497
+7,965
+43% +$80.4K
CMPX icon
275
Compass Therapeutics
CMPX
$387M
$277K 0.08%
+51,556
New +$238K
9 10
11
12 13

Similar funds

RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return
MS
Millington Securities Red Bank, New Jersey $362M AUM
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
HS
HighVista Strategies Boston, Massachusetts $362M AUM 230.96% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
A6
Anchor @ 65 Singapore $362M AUM 20.02% 1-Year Est. Return
ACM
Anfield Capital Management Irvine, California $363M AUM 24.08% 1-Year Est. Return

Virtus Investment Advisers's Q4 2025 Portfolio in Review

As of Q4 2025, Virtus Investment Advisers held 553 positions worth $368M, up 5.3% from $349M the previous quarter. Its ten largest holdings account for 6.4% of the portfolio.

Virtus Investment Advisers deployed $14.9M of net new capital in Q4 2025, opening 113 new positions and adding to 199 existing holdings. Its largest new stake was Expeditors International: 15,974 shares worth $2.38M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, up from 17% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was VICI Properties, an estimated $1.66M trimmed.

  • Virtus Investment Advisers's largest Q4 2025 buy was Expeditors International: 15,974 shares worth $2.38M.
  • Virtus Investment Advisers added most to Incyte in Q4 2025, an estimated $2.09M increase.
  • Virtus Investment Advisers's biggest Q4 2025 reduction was VICI Properties, cutting an estimated $1.66M.
  • Virtus Investment Advisers fully exited Tesla in Q4 2025, selling an estimated $2.5M.
  • Virtus Investment Advisers's ten largest holdings make up 6.4% of its $368M portfolio in Q4 2025.
  • Virtus Investment Advisers opened 113 new positions and closed 92 in Q4 2025.
  • Virtus Investment Advisers's portfolio value rose 5.3% quarter-over-quarter to $368M.

Based on Virtus Investment Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.